Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript
09:17pm, Wednesday, 07'th May 2025
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Andrew McKibben - SVP, Strategic Finance and IR Chris Peetz - CEO Peter Radovich
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
06:30pm, Wednesday, 07'th May 2025
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.54 per share a year ago.
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 07'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update.
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities
06:45pm, Sunday, 04'th May 2025
Mirum Pharmaceuticals boasts a strong portfolio with LIVMARLI, Ctexli, and Cholbam, as well as two promising pipeline candidates --volixibat and MRM-3379-- both of which carry billion-dollar potential
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
08:30am, Wednesday, 30'th Apr 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025.
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
08:30am, Monday, 28'th Apr 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses.
Mirum's LIVMARLI Now FDA Approved in Tablet Formulation
08:30am, Monday, 14'th Apr 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #alagillesyndrome--Mirum's LIVMARLI Now FDA Approved in Tablet Formulation.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00pm, Thursday, 10'th Apr 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
LIVMARLI Now Approved in Japan for ALGS and PFIC
08:30am, Thursday, 27'th Mar 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC.
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
05:17pm, Monday, 24'th Mar 2025
Mirum Pharmaceuticals, Inc. stock has risen nearly 25% since my "Sell" rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cho
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
01:40pm, Friday, 21'st Mar 2025
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00pm, Monday, 10'th Mar 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
11:25am, Thursday, 27'th Feb 2025
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript
07:10am, Thursday, 27'th Feb 2025
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Rela
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
06:16pm, Wednesday, 26'th Feb 2025
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.66 per share a year ago.
